Novo’s New Wegovy Pill Surges Out of the Gate
Novo Nordisk’s oral Wegovy is off to a strong start, with Week 2 prescriptions around 18,000–20,000, reportedly higher than the initial weeks of injectable Wegovy and Lilly’s Zepbound. Analysts say the rapid uptake could help Novo regain obesity market share as it faces competition from Lilly’s orforglipron and Zepbound’s dominance; the pill is priced at $149 per 1.5 mg dose (cash) with insured patients potentially paying as low as $25 per month, and Novo’s stock has risen about 20% this year in response.
